此外，君实生物公布，8月24日至10月8日，LVC Renaissance Fund、LVC Fund I及LVC Fund II及因基金期限与流动性资金安排减持公司H股股份，合计约824.1万股H股。此外，10月23日至10月29日，上海檀英与上海檀正通过集中竞价方式合计减持公司A股股份218.379万股。上述减持完成后，持股5%以上股东上海檀英及其一致行动人合计持有的公司股份比例从10.7876%减少至9.7300%，持股比例减少超过1%。Junshi Bio (01877) is now falling by over 4%, as of the time of writing, it has dropped by 4.2%, to 13.24 Hong Kong dollars, with a turnover of 11.964 million Hong Kong dollars.
According to the Wisdom Financial News APP, Junshi Bio (01877) is now falling by over 4%, as of the time of writing, it has dropped by 4.2%, to 13.24 Hong Kong dollars, with a turnover of 11.964 million Hong Kong dollars.
On the news front, Junshi Bio announced that in the first three quarters of 2024, the revenue was 1.271 billion yuan, a year-on-year increase of 28.87%; with a net loss of 0.927 billion yuan. The third-quarter revenue was 0.485 billion yuan, a year-on-year increase of 53.16%; with a net loss of 0.282 billion yuan. It is worth noting that in the third quarter, the domestic sales revenue of Toripalimab reached 0.397 billion yuan, an increase of nearly 80% year-on-year.
In addition, Junshi Bio announced that from August 24 to October 8, LVC Renaissance Fund, LVC Fund I, and LVC Fund II reduced their holdings of the company's listed in Hong Kong shares by a total of approximately 8.241 million H shares. Furthermore, from October 23 to October 29, Shanghai Tan Ying and Shanghai Tan Zheng collectively reduced their holdings of the company's A shares by 2.18379 million shares through centralized bidding. After the aforementioned shareholding reductions, the proportion of shares held by shareholders with more than 5% shares, Shanghai Tan Ying, and their concerted action parties decreased from 10.7876% to 9.7300%, a decrease of more than 1% in shareholding percentage.
